Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.

ABSTRACT:

Importance

Psilocybin shows promise as a treatment for major depressive disorder (MDD).

Objective

To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD.

Design, setting, and participants

In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were randomized in a 1:1 ratio to receive a single dose of psilocybin vs niacin placebo administered with psychological support. Participants were adults aged 21 to 65 years with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of MDD of at least 60 days' duration and moderate or greater symptom severity. Exclusion criteria included history of psychosis or ma

SUBMITTER: Raison CL 

PROVIDER: S-EPMC10472268 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature